美罗华
医学
维持疗法
免疫抑制
肉芽肿伴多发性血管炎
显微镜下多血管炎
血管炎
抗中性粒细胞胞浆抗体
免疫学
耐受性
内科学
疾病
抗体
不利影响
化疗
作者
Naomi J Patel,John H. Stone
摘要
The antineutrophil cytoplasmic antibody (ANCA)–associated vasculitides (AAV) comprise a major subset of diseases that cause destructive inflammation of small and medium‐sized blood vessels. Although these conditions have a predilection for pulmonary and renal involvement, they are in fact protean diseases that can involve essentially any organ system. AAV is among the most difficult rheumatic diseases to diagnose and treat. Therapy for AAV has evolved over the past two decades. Rituximab, an anti‐CD20 monoclonal antibody, is now the preferred agent for remission induction in conjunction with a reduced‐dose glucocorticoid taper. Rituximab is also often a key therapy for remission maintenance. Glucocorticoid toxicity reduction has become a major priority for treatment regimens. Avacopan, an important new adjunct to remission induction therapy, may reduce glucocorticoid use and its resulting toxicity. The role of avacopan as a remission maintenance agent requires further study. The duration of immunosuppression following remission is guided by a number of factors, including the patient's overall clinical state, the degree of damage from previous disease activity, the tolerability of remission maintenance medications, and SARS–CoV‐2 vaccination and immunity status. Certain features, including history of previous relapse, the presence of ANCA directed against proteinase 3, and a diagnosis of granulomatosis with polyangiitis, favor prolonged remission maintenance therapy. The interval between rituximab doses can usually be lengthened over time during the maintenance phase.
科研通智能强力驱动
Strongly Powered by AbleSci AI